Clinical Trials Logo

Clinical Trial Summary

The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promotes the transfer of the latest scientific knowledge into standard care. The DigiNet project is based on the established precision medicine program, the National Network Genomic Medicine Lung Cancer (nNGM) in Germany, whereby every patient receives molecular diagnostics and personalized therapy information after the initial diagnosis. Within the framework of the DigiNet project, specialized academic centers will be digitally connected with practitioners via a shared project database. Furthermore, a committee of experts will monitor the course of treatment and will advise the practitioners in case of critical conditions. Additionally, patient-reported outcomes will be incorporated into the treatment.


Clinical Trial Description

The aim of the DigiNet project is to prospectively evaluate a precision medicine program for lung cancer and to improve personalized care of patients with advanced non-small cell lung cancer (NSCLC) through a collaboration of specialized academic centers with routine care providers (hospitals, oncology practices). The use of targeted therapies will be regularly monitored and guided through a shared digital database. Patients with an initial diagnosis of stage IV NSCLC in the study regions (study region east: Berlin and Saxony; study region west: North Rhine-Westphalia) are included. DigiNet builds on the foundations and structures of the National Network Genomic Medicine Lung Cancer (nNGM) in Germany, which provides molecular diagnostics and treatment information to the participating physicians based on the latest evidence. Within the framework of DigiNet, patients are regularly consulted by the study practitioners and the clinical data is documented in a structured manner in a central project database. Through the digital collaboration of the nNGM network centers via the shared project database with the practitioners in routine care, continuous monitoring of the course of treatment and, in the case of critical conditions, treatment guidance by an expert committee advising the practitioner is provided. In addition, the patients routinely assess the quality of life (EORTC QLQ-C30, EORTC QLQ-LC29, EQ-5D), as well as anxiety and depression (PHQ-4). The results of these patient-reported outcomes (PROs) are incorporated into the treatment by the practitioners (patient-centered treatment approach). The evaluation of the project is structured into different core domains: An evaluation of clinical endpoints, process parameters (implementation of the intervention), and health economic evaluations will be conducted. The acceptance and potential for improvement of the project will be assessed through qualitative interviews with the stakeholders. Data from the state cancer registries of the study regions will be incorporated to generate a population-based comparative cohort for the evaluation of the main research questions of DigiNet, thereby representing patients receiving routine care in Germany. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05818449
Study type Interventional
Source University of Cologne
Contact
Status Active, not recruiting
Phase N/A
Start date June 1, 2022
Completion date March 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT02047344 - Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC Phase 2
Terminated NCT00766246 - Phase II Avastin Trial for Stage IIIB/IV NSCLC Phase 2
Active, not recruiting NCT04108026 - Immunotherapy in Patient With Poor General Condition Phase 2
Active, not recruiting NCT04432207 - A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05598853 - Intrathecal Double Checkpoint Inhibition Phase 1
Not yet recruiting NCT06117644 - The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Terminated NCT01348126 - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Phase 2/Phase 3
Completed NCT01086254 - SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer Phase 2
Terminated NCT01798485 - A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Phase 3
Recruiting NCT06348199 - A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer Phase 3
Not yet recruiting NCT06436144 - Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC Phase 2
Terminated NCT04289259 - Tumor Mutational Burden in Lung Cancer Patients
Completed NCT03526900 - Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis Phase 2
Not yet recruiting NCT06463665 - Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) Phase 2
Completed NCT02176369 - Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial Phase 2
Terminated NCT03275597 - Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition Phase 1
Completed NCT02450539 - A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT05055167 - Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC Phase 2
Not yet recruiting NCT03532698 - Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
Not yet recruiting NCT03543683 - Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC